Department of Food and Nutrition, Chung-Ang University, 4726 Seodong-daero, Daedeok-myeon, Anseong 17546, South Korea.
Department of Integrated Biomedical and Life Sciences, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, South Korea; BK21 FOUR R&E Center for Learning Health Systems, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, South Korea.
Int J Biol Macromol. 2023 Dec 31;253(Pt 1):126560. doi: 10.1016/j.ijbiomac.2023.126560. Epub 2023 Aug 26.
The present study aimed to investigate the effect of oral administration of snail-derived mucin extract (SM) on ameliorating constipation symptoms of loperamide-induced constipated rats (n = 6). The analytical results indicated that SM mainly contains a glucan-rich snail mucin heteropolysaccharide with high molecular weights (108.5-267.9 kDa), comprising primarily of glucose (64.9 %) and galactose (22.4 %) with some deoxyhexoses (5.0 %) and hexosamines (4.9 %). Daily SM administration at doses of 10-40 mg/kg/day to the loperamide-induced constipated rats significantly (p < 0.05) ameliorated the deterioration in fecal parameters, such as numbers and weight of feces, fecal water contents, and gastrointestinal transit ratio. The histomorphometric results showed that the loperamide-induced decreases in the thickness of mucosal and muscularis mucosae layers as well as the distribution of mucin and c-KIT-positive areas were significantly (p < 0.05) improved via SM consumption at all doses tested. SM administration at all doses significantly increased the expression of genes encoding tryptophan hydroxylases (TPH1 and TPH2; p < 0.05), tight junction molecules (OCLN, CLDN1, and TJP1; p < 0.05), and mucin (MUC2 and MUC4; p < 0.05), but significantly decreased the aquaporin-encoding genes (AQP3 and AQP8; p < 0.05). Gut microbial community analysis indicated that SM administration could modulate loperamide-induced dysbiosis by increasing the phyla Actinobacteria (11.72-12.64 % at 10-40 mg/kg doses; p < 0.05) and Firmicutes (79.33 % and 74.24 % at 20 and 40 mg/kg doses; p < 0.05) and decreasing the phyla Bacteroidetes (5.98-12.47 % at 10-40 mg/kg doses; p < 0.05) and Verrucomicrobia (2.21 % and 2.78 % at 20 and 40 mg/kg doses; p < 0.05), suggesting that SM administration is effective in ameliorating constipation by controlling gut microbial communities. These findings can be utilized as fundamental data for developing novel functional materials using SM to prevent or treat constipation.
本研究旨在探讨蜗牛源黏蛋白提取物(SM)口服给药对改善洛哌丁胺诱导的便秘大鼠(n=6)便秘症状的作用。分析结果表明,SM 主要含有富含葡聚糖的蜗牛黏蛋白杂多糖,其分子量较高(108.5-267.9 kDa),主要由葡萄糖(64.9%)和半乳糖(22.4%)组成,还有一些去氧己糖(5.0%)和己糖胺(4.9%)。每天以 10-40mg/kg 的剂量向洛哌丁胺诱导的便秘大鼠给予 SM 治疗,可显著(p<0.05)改善粪便参数的恶化,如粪便数量和重量、粪便含水量以及胃肠道转运比。组织形态计量学结果表明,SM 可显著改善洛哌丁胺诱导的黏膜和黏膜肌层厚度以及黏蛋白和 c-KIT 阳性区域分布的降低(p<0.05)。所有测试剂量的 SM 治疗均可显著增加编码色氨酸羟化酶(TPH1 和 TPH2;p<0.05)、紧密连接分子(OCLN、CLDN1 和 TJP1;p<0.05)和黏蛋白(MUC2 和 MUC4;p<0.05)的基因表达,但显著降低水通道蛋白编码基因(AQP3 和 AQP8;p<0.05)的表达。肠道微生物群落分析表明,SM 治疗可通过增加厚壁菌门(11.72-12.64%,在 10-40mg/kg 剂量下;p<0.05)和Firmicutes 门(79.33%和 74.24%,在 20 和 40mg/kg 剂量下;p<0.05),减少拟杆菌门(11.72-12.64%,在 10-40mg/kg 剂量下;p<0.05)和 Verrucomicrobia 门(2.21%和 2.78%,在 20 和 40mg/kg 剂量下;p<0.05),来调节洛哌丁胺诱导的肠道菌群失调,提示 SM 治疗通过控制肠道微生物群落来有效改善便秘。这些发现可作为使用 SM 开发新型功能性材料以预防或治疗便秘的基础数据。